DELRAY BEACH, FL / ACCESSWIRE / February 11, 2016 / As America experiences a culture shift instigated by increasingly progressive legislation regarding cannabis, medicinal therapies using the drug continue to garner acceptance across the country. One company capitalizing on this trend is Cannabis Science, Inc (CBIS), which has developed and distributed an array of cannabinoid products beginning to gain traction in the marketplace.

In recent months, Cannabis Science has worked to expand the scope of its business into a variety of ventures that should start to produce new revenue streams for the company in the near future. One such milestone for the company was Monday's announcement naming autism as the company's next targeted ailment. In fact, Cannabis Science added Mieko Hester-Perez, noted public spokesperson for the success of cannabis in the treatment of autism, as the newest member of the company's Scientific Advisory Board.

Ms. Perez has triumphed the cause of medicinal cannabis use for autistic children for several years after arriving at a successful treatment plan for her son using the drug. A customized cannabis formulation, called "Joey's Strain," was infamously created to treat the boy, sparking widespread media coverage. Cannabis Science has initiated preliminary protocols for formal studies with Ms. Perez and her specific research methods.

Additionally, Cannabis Science expanded its ever-growing product line with the release of "Jimi's Meds," a product line using varying dosages of CBD, THCa, and THC, marketed to self-medicating licensed consumers in California. The product release is the result of the company's fertile partnership with Purple Haze Properties, a company co-headed by Leon Hendrix, the late guitar-slinger's brother. Purple Haze Products and Cannabis Science are expected to team up to release more future products, yet to be announced as of press time.

Meanwhile, a series of capsule-based products set for release by Cannabis Science recently underwent consumer feedback and test marketing. The results indicated that consumers gave the products glowing reviews. Cannabis Science plans to use this feedback, along with the company's own proprietary information, to fine tune these products prior to their wide-scale initial release in California's diverse dispensaries market.

"This positive response has made Cannabis Science management optimistic about our national rollout [of these products] in the near future," said President, CEO, and Co-Founder Raymond C. Dabney, who was deeply encouraged by the consumer data.

As if these ventures weren't enough to diversify Cannabis Science's wide-ranging portfolio of interests, the company's wholly-owned subsidiary, Equi-Pharm, unleashed its e-Commerce site last month, granting nationwide consumers access to the company's Quality Animal Care Products, such as Equi-Sheen HP, a hemp-infused grooming product for horses. While Equi-Farm previously serves a local, niche market, the move places the company in an ideal position to increase revenue streams exponentially through greater exposure to its entire line of products.

While firmly keeping its hand in all of these interests, Cannabis Science also declared forward-looking guidance regarding research and development for several of its proprietary drugs, including CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, working closely with European partner ImmunoClin to expedite its clinical goals for these products.

With numerous products and projects in the pipeline, Cannabis Science remains one of the most ambitious, exciting companies to watch in the industry of cannabinoid therapies and medicinal cannabis products. Speculative investors expect plenty more significant moves for 2016 as the company continues to grow and expand its revenue potential.

Other Micro Caps Worth A Mention....Tickers INCT, SHRK, PSID

(INCT) Qwote and Bahja Rodriquez Sign With Play Celebrity Games for Production of Game Apps

SAN DIEGO CA-- Feb 11, 2016) - InCapta, Inc. (OTC PINK: INCT), and its subsidiaries Play Celebrity Games and Stimulating Software, announce that Qwote and Bahja Rodriquez have signed to have Play Celebrity Games produce and launch game apps for their fan base.

Stimulating Software launched five new mobile game apps that are available to install in the app stores of Google, Apple, Amazon and other stores internationally. The company is excited to see its mobile games apps reaching the public.

Qwote commented: "I am excited to work with Play Celebrity Games and look forward to expanding the way in which my fans can interact with me."

(SHRK) SharkReach, Inc. Reaches Agreement To Acquire Key Strategic Instagram Partner With Presently Projected 2016 Revenues of $1.5 Million

The Mobile Media Lab Has Been Described As "A Marketing Agency For Instagram" By Adweek

HERMOSA BEACH, California, February 11, 2016 /--SharkReach, Inc. ("SharkReach(R)" or the "Company") (OTC Markets: SHRK) a millennial influence marketing company today announced that it has reached an agreement to acquire 100% of a key strategic partner in the millennial social media marketplace.

Under the terms of the agreement, at Closing the Company will acquire 100% of The Mobile Media Lab, LLC for cash and stock in the Company. Closing is scheduled to take place on or before February 28, 2016 but can be extended thirty days by agreement of the parties. Details of the transaction will be released in an upcoming 8K filing.

(PSID) PositiveID Corporation's Thermomedics' Subsidiary Signs Deals with Five New Healthcare Products Distributors in January

DELRAY BEACH, Florida, February 11, 2016 /--PositiveID Corporation ("PositiveID" or "Company") (PSID), a life sciences company focused on detection and diagnostics, announced today that its Thermomedics subsidiary, which markets the Caregiver® FDA-cleared non-contact thermometer, made significant progress on its growth plan in January 2016, including entering into agreements with five new healthcare products distributors, increasing sequential monthly sales growth, and establishing several near-term pipeline opportunities.

Seraphim Strategies is a third party publisher. Not a registered broker/dealer/analyst/adviser, holds no investment licenses and may not sell, offer to sell or offer to buy any security. Market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is not to be interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. For full disclaimer please read http://tomorrowsbluechips.com/disclaimer/ This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually," or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Seraphim Strategies LLC
801-988-6474

SOURCE: Seraphim Strategies LLC